Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multi-center, Exploratory Dose-response Study to Assess the Efficacy and Safety of Different Oral Doses of BAY1128688 in Women With Symptomatic Endometriosis Over a 12-week Treatment Period

Next Previous
X
Search
Trial Profile

A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multi-center, Exploratory Dose-response Study to Assess the Efficacy and Safety of Different Oral Doses of BAY1128688 in Women With Symptomatic Endometriosis Over a 12-week Treatment Period

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BAY 1128688 (Primary)
  • Indications Endometriosis; Pelvic pain
  • Focus Therapeutic Use
  • Acronyms AKRENDO1
  • Sponsors Bayer

    • Most Recent Events

    • 09 Jul 2023 Results of a clinical trial (AKRENDO1) the effects of BAY1128688 in adult premenopausal women with endometriosis-related pain symptoms over a 12-week treatment period published in the Drugs in R and D
    • 28 Feb 2019 This trial was discontinued in Netherlands, according to European Clinical Trials Database.
    • 29 Nov 2018 Status changed from active, no longer recruiting to discontinued.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top